Key Points
- CFO Houte Hans Van sold 3,661 shares on Jan. 30 at an average price of $16.60 for about $60,773, reducing his stake by 7.46% to 45,427 shares; other insiders also sold shares the same day.
- Nurix reported Q4 EPS of ($0.82) versus the ($0.84) estimate and revenue of $13.58M, but continues to show a negative return on equity (−57.51%) and a deeply negative net margin (−314.90%).
- Analysts and institutions remain largely bullish—MarketBeat consensus is a "Moderate Buy" with a $29.50 target and multiple firms have maintained or raised price targets—though TipRanks flagged material foreign‑exchange risk that could increase earnings volatility.
Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 3,661 shares of the stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $60,772.60. Following the completion of the sale, the chief financial officer owned 45,427 shares in the company, valued at approximately $754,088.20. This trade represents a 7.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Houte Hans Van also recently made the following trade(s):
- On Monday, November 3rd, Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock. The shares were sold at an average price of $12.56, for a total transaction of $78,927.04.
Nurix Therapeutics Stock Performance
NASDAQ:NRIX opened at $16.52 on Friday. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -5.43 and a beta of 1.93. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $22.50. The stock has a fifty day moving average price of $18.50 and a 200-day moving average price of $13.36.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Wednesday, January 28th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.02. Nurix Therapeutics had a negative return on equity of 57.51% and a negative net margin of 314.90%.The firm had revenue of $13.58 million during the quarter, compared to the consensus estimate of $13.41 million. Research analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.
Hedge Funds Weigh In On Nurix Therapeutics
Several institutional investors have recently bought and sold shares of the company. Pictet Asset Management Holding SA grew its holdings in Nurix Therapeutics by 75.1% during the fourth quarter. Pictet Asset Management Holding SA now owns 3,467,600 shares of the company's stock valued at $65,780,000 after purchasing an additional 1,487,060 shares during the period. Vestal Point Capital LP raised its stake in shares of Nurix Therapeutics by 73.8% in the third quarter. Vestal Point Capital LP now owns 3,475,000 shares of the company's stock valued at $32,109,000 after buying an additional 1,475,000 shares during the period. Vanguard Group Inc. lifted its position in shares of Nurix Therapeutics by 32.5% during the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company's stock valued at $112,862,000 after buying an additional 1,460,736 shares during the last quarter. Perceptive Advisors LLC grew its stake in shares of Nurix Therapeutics by 268.7% during the 2nd quarter. Perceptive Advisors LLC now owns 1,096,985 shares of the company's stock worth $12,495,000 after acquiring an additional 799,432 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Nurix Therapeutics by 84.1% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,391,638 shares of the company's stock worth $15,851,000 after acquiring an additional 635,668 shares during the period.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Nurix Therapeutics in a research report on Thursday, January 22nd. Morgan Stanley set a $36.00 price objective on shares of Nurix Therapeutics and gave the company an "overweight" rating in a research note on Thursday, January 8th. Wells Fargo & Company cut their target price on Nurix Therapeutics from $30.00 to $29.00 and set an "overweight" rating on the stock in a research note on Thursday. Piper Sandler upped their target price on Nurix Therapeutics from $32.00 to $35.00 and gave the company an "overweight" rating in a report on Thursday. Finally, Royal Bank Of Canada lifted their price target on Nurix Therapeutics from $28.00 to $30.00 and gave the stock an "outperform" rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Nurix Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.50.
View Our Latest Stock Analysis on NRIX
Key Stories Impacting Nurix Therapeutics
Here are the key news stories impacting Nurix Therapeutics this week:
- Positive Sentiment: Royal Bank of Canada raised its price target on NRIX to $30 and maintained an outperform view, signaling significant upside versus the current stock level. RBC increases price target to $30
- Positive Sentiment: Needham & Company reaffirmed a "buy" rating with a $26 target and BTIG reiterated a buy with a $30 target — multiple brokerages maintaining bullish outlooks provide support for upside expectations. Needham and BTIG ratings
- Negative Sentiment: Insiders sold shares on Jan. 30: Gwenn Hansen sold 4,895 shares at ~$16.60 and CFO Houte Hans Van sold 3,661 shares at ~$16.60. Insider sales can be viewed negatively by the market because they reduce insider ownership and may signal cashing out. SEC filings: Hansen Form 4 and Van Form 4
- Negative Sentiment: TipRanks highlighted a newly disclosed material foreign‑exchange risk for Nurix due to unhedged currency exposure, which could increase earnings volatility and raise capital‑markets uncertainty. TipRanks: FX risk disclosed
Nurix Therapeutics Company Profile
(
Get Free Report)
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company's pipeline includes multiple programs in various stages of development.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
